Skip to main content
Figure 5 | Arthritis Research & Therapy

Figure 5

From: Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project

Figure 5

Prescription of disease-modifying anti-rheumatic drugs in patients with different anti-cyclic citrullinated peptide status. Diagram to illustrate the prescription of disease-modifying anti-rheumatic drugs (DMARDs) at different time points after enrolment of patients with different anti-cyclic citrullinated peptide (aCCP) status. Prescribing physicians were unaware of the aCCP results.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us